Media headlines about Cerus (NASDAQ:CERS) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cerus earned a news sentiment score of 0.18 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 45.2701454671963 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

These are some of the headlines that may have effected Accern Sentiment Analysis’s rankings:

A number of research analysts have commented on the company. Zacks Investment Research cut Cerus from a “buy” rating to a “hold” rating in a research note on Wednesday, January 3rd. BidaskClub cut Cerus from a “hold” rating to a “sell” rating in a research note on Tuesday, December 12th. Robert W. Baird restated a “buy” rating and set a $5.00 price objective on shares of Cerus in a research note on Friday, December 1st. ValuEngine upgraded Cerus from a “strong sell” rating to a “sell” rating in a research note on Thursday, January 4th. Finally, BTIG Research reiterated a “neutral” rating on shares of Cerus in a research note on Friday, December 8th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $5.83.

Cerus (CERS) opened at $4.32 on Friday. The company has a quick ratio of 3.11, a current ratio of 3.71 and a debt-to-equity ratio of 0.80. Cerus has a one year low of $1.93 and a one year high of $4.70. The company has a market capitalization of $492.85, a PE ratio of -7.32 and a beta of 1.93.

Cerus (NASDAQ:CERS) last released its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.12) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.03. Cerus had a negative return on equity of 142.18% and a negative net margin of 159.35%. The business had revenue of $10.80 million for the quarter, compared to analysts’ expectations of $11.95 million. During the same quarter in the previous year, the firm posted ($0.14) earnings per share. The company’s revenue was up 5.9% compared to the same quarter last year. analysts forecast that Cerus will post -0.57 EPS for the current year.

WARNING: This report was first reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at

About Cerus

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Insider Buying and Selling by Quarter for Cerus (NASDAQ:CERS)

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with's FREE daily email newsletter.